Open AccessComparison of AdvanSure HPV GenoBlot and Hybrid Capture 2 assays for detection of HPV infection
Author(s) -
Ko Kiwoong,
Yu Shinae,
Kwon MinJung,
Lee Eun Hee,
Woo HeeYeon,
Park Hyosoon
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22161
Subject(s) - hybrid capture , human papillomavirus , genotyping , genotype , kappa , virology , medicine , microbiology and biotechnology , biology , cervical intraepithelial neoplasia , cervical cancer , gene , genetics , cancer , linguistics , philosophy
Background We sought to compare the performance of the AdvanSure assay to the Hybrid Capture ( HC ) 2 for the detection of high‐risk human papillomavirus ( HR HPV ). Methods A total of 855 cervical swab specimens were obtained. We submitted all specimens for HR HPV detection with HC 2 and the AdvanSure assay. We subsequently analyzed discordant results and specimens that were positive on both assays using restriction fragment mass polymorphism ( RFMP ) genotyping analysis. Results HC 2 yielded positive results in 12.0% of specimens, while the AdvanSure assay detected one of 13 HR HPV types in 11.5% of specimens. The overall agreement rate between the assays was 98.5% with a kappa coefficient of 0.928. Discordant results between these two assays were observed in 12 cases, seven were positive only on HC 2 and five were positive only on AdvanSure. RFMP analysis of the 12 discordant cases revealed three false‐positive results using HC 2, and one false‐positive and five false‐negative results using AdvanSure. Conclusions Considering the high agreement rate with HC 2 and the ability to differentiate 35 HPV genotypes including HPV 16/18, the AdvanSure assay could be used as a laboratory testing method for HPV infection screening.